Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

The treatment of steroid refractory acute graft-versus-host disease has been a significant clinical challenge. There have been relatively few randomized clinical trials comparing different treatment options. One such approach was the use of inolimomab (an anti-CD25 monoclonal antibody that blocks interleukin-2 signaling) that was compared to antithymocyte globulin in the INO107 phase 3 trial. Socié and colleagues report on the long-term follow-up of patients treated on this trial.